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The pharmacokinetics of ciprofloxacin excretion have been studied in 54 patients undergoing biliary and
pancreatic operations with and without obstruction of the common bile duct. High concentrations were
achieved in common duct bile within 20 minutes of intravenous injection and persisted for over 3 hours
after 100 mg and for over 8 hours after 200 mg. The concentration of ciprofloxacin in the bile offunctioning
gall bladders was much greater than that in the common duct bile. Remarkably, it was identified in
therapeutic concentrations in the bile of obstructed ducts. This and the rapid fall from initially high venous
concentrations probably reflect diffusion from the circulation as a result of the exceptional tissue
penetration. A unique feature of this study was the finding of clinically significant concentrations in the
bile of obstructed ducts.
Two patients developed wound infection and no side effects were observed. The broad spectrum
antibiotic ciprofloxacin has potential as a useful agent for prophylaxis in biliary surgery maintaining biliary
and venous concentrations in excess of the MIC90 for most biliary pathogens for more than 8 hours.
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INTRODUCTION
Septic complications are common after biliary surgery performed without
prophylactic antibiotics1-3 but are uncommon when prophylactic antibiotics have
been used2’4. Ciprofloxacin is a quinolone related to nalidixic acid but having a
broader spectrum of antimicrobial activity and fewer side effects5. Its spectrum of
activity suggested to us that it might be useful as a prophylactic antibiotic in patients
undergoing biliary surgery.
MATERIALS AND METHODS
Sixteen male and 38 female patients aged 22-86 years gave written informed consent
for entry into the study. Seventeen showed some degree of obstruction to the
drainage of bile due to stones (9), pancreatic carcinoma (5), carcinoma of the
ampulla of Vater (1), carcinoma of the common bile duct (1) and acute pancreatitis
(1).
Ciprofloxacin was injected intravenously as a single dose at varying times up to 8
hours before anaesthetic induction. Thirty-two patients were given 100 mg and 22
were given 200 mg. At operation samples were taken of common duct and gall
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bladder bile and venous blood. The time of infusion and sampling was recorded and
samples were stored in oxalate at -20C until analysed by high performance liquid
chromatography.
RESULTS
Two patients suffered wound infections and no adverse reactions to ciprofloxacin
were observed. One patient developed an infection 9 days after cholecystectomy and
Staphylococcus aureus of a phage type known to be prevalent in the hospital was
isolated suggesting that this infection was exogenous. Another occurred 14 days after
cholecystectomy, 1 week after discharge from hospital and swabs for culture were
not obtained.
Patients with an obstructed common bile duct (CBD) were classed into partial or
complete obstruction (Table 1) on the basis of the clinical picture, operative findings,
radiological investigations and degree of disturbance of liver biochemistry. In 5
patients the common bile duct sample was insufficient for assay.
A series of mathematical models were examined to determine whether the time
since infusion and/or degree of common bile duct obstruction could be used to
predict ciprofloxacin concentrations in both venous blood and the common bile duct.
The models were developed using the method of maximum likelihood6; significance
of the model parameters was set at the conventional 5% level. Optimum prediction
was obtained when both the ciprofloxacin concentrations and times since infusion
were converted to natural logarithms. The calculations were performed using the
GLIM 3.77 computer package
7 at the University of Manchester Regional Computer
Centre.
Venous Blood
The prediction model for venous blood concentrations is detailed in Table 2 (i and ii).
The agreement between the model predictions and the observed assay values for the
100 mg dose are shown graphically in Figure 1. A similar representation of the 200
mg dose data is shown in Figure 2; the numbers of patients with partial and total
obstruction receiving 200 mg were too small for the derived prediction curves to be
considered acceptable for clinical use, so these curves were not plotted.
Venous blood concentration was found to fall exponentially with time.
Concentrations were consistently higher with the 200 mg dose than with the 100 mg
dose. This difference was significantly more marked in the presence of partial
obstruction (p 0.002).
Table 1 Classification of degree of common bile duct obstruction.
Dose 100mg 200mg
Obstruction Nil Partial
No. of
patients 19 8
Complete Nil
5 18
Pirtial CompleteTHE PHARMACOKINETICS OF THE BILIARY EXCRETION OF CIPROFLOXACIN 321
Table 2 Analysis of venous blood concentrations- derivation of predicted values
(i) Analysis ofvariance table
Source
Time
Dose
Obstruction
Dose obstruction
Lack of fit
Residual
Degrees of
Freedom
2
2
3
36
Mean Square
21.160
5.489
0.539
1.698
0.041
0.212
F-ratio
99.864
25.905
2.544
8.014
0.193
Probability
0.001
0.001
0.091
0.002
0.900
The mathematical model fitted is shown below. The figures in brackets are the standard errors of the
model parameter estimates:
log (conc.) (-0.652 log t) + K where time in minutes
(0.66)
where K is obtained from the following table"
(ii)
Dose
Obstruction
K
(Standard error)
100mg
Nil Partial
2.590 2.382
(0.312) (0.367)
Complete
2.844
(0.392)
200mg
Nil Partial
3.087 4.496
(0.325) (0.429)
Example time 30 minutes, dose 100 mg., obstruction partial
Then log(conc) (-0.652 log(30)) + 2.382 0.164
Thus estimated blood conc. at 30 minutes on 100 mg 1.178 mg/l.
Complete
3.894
(0.551)
Common Bile Duct
The prediction model for common bile duct concentrations is detailed in Table III (i
and ii). The agreement between the model predictions and the observed assay values
are shown graphically in Figures 3 and 4. As for the venous blood data, only the
prediction curve for unobstructed common bile ducts is reported for the 200 mg dose
level.
Again, ciprofloxacin concentration fell exponentially with time, and
concentrations were consistently higher with the 200 mg dose than with the 100 mg
dose. On both doses the concentrations decreased significantly as the degree of
obstruction increased.
Gall Bladder Bile
In four patients no sample was obtained due to biliary sludge (3) or previous
cholecystectomy (1). In 11 patients ciprofloxacin concentration was greater in gall
bladder bile than in common bile duct bile and in 2 it was 18 times that found in the
common duct. In 7 of the 11 patients a pre-operative oral cholecystogram was
available showing a functioning gall bladder. The other 4 had pre-operative
ultrasound only for diagnosis of gallstones.322 C.S. BALL et al.
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Figure 1 Ciprofloxacin venous blood level (mg/l) following a 100mg iv bolus dose, administered at varying
times up to 8 hours before induction of anaesthesia, in patients with unobstructed (*) partially obstructed
(o) or completely obstructed (o) common bile ducts (CBDs). Comparison with predicted ciprofloxacin
venous blood levels for unobstructed (.. ), partially obstructed (--) and completely
obstructed CBDs.
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Figure 2 Ciprofloxacin venous blood levels (mg/l) following a 200mg iv bolus dose, administered at
varying times up to 8 hours before induction of anaesthesia, in patients with unobstructed (*), partially
obstructed (o) or completely obstructed (o) CBDs. Comparison with predicted ciprofloxacin venous
blood levels for unobstructed CBDs(-- .).THE PHARMACOKINETICS OFTHE BILIARY EXCRETION OF CIPROFLOXACIN 323
Table 3 Analysis of common bile duct concentrations derivation of predicted values
(i) Analysis of variance table
Source
Time
Dose
Obstruction
Dose obstruction
Lack of fit
Residual
Degrees of
Freedom
2
2
3
36
Mean Square
16.373
1.834
3.913
0.647
0.602
0.238
F-ratio
68.373
7.692
16.412
2.714
2.526
Probability
0.001
0.009
0.001
0.078
0.072
The mathematical model fitted is shown below The figures in brackets are the standard errors of the
model parameter estimates:
log (conc.) (-0.489 log t) + K where time in minutes
(0.075)
where K is obtained from the following table:
(ii)
Dose 100mg
Obstruction Nil Partial
K 3.727 3.335
(Standard error) (0.357) (0.402)
Complete
2.619
(0.436)
200mg
Nil Partial
4.154 3.762
(0.358) (0.418)
Example: time 30 minutes, dose 100 mg., obstruction partial
Then" log(conc) (-0.489 log(30)) + 3.335 1.672
Thus: estimated blood conc. at 30 minutes on 100 mg 5.323 mg/1.
Complete
3.046
(0.454)
DISCUSSION
The high serum concentrations of ciprofloxacin fell rapidly during the first hour after
infusion. Higher concentrations were maintained for longer with the 200 mg dose
than with the 100 mg dose. This early fall in serum concentrations may reflect the
rapid dispersal of the drug due to its exceptional tissue penetration8. The antibiotic
rapidly occupies a large volume of distribution (2 1/kg) and after 4 hours decreasing
serum concentrations are due solely to elimination of the drug. The kidneys are the
major route of elimination of ciprofloxacin and its clearance is twice that of
creatinine, indicating active tubular secretion9.
Studies with other antibiotics have shown serum concentrations to be increased by
10 duct obstruction A similar phenomenon was observed in this study but the
magnitude was less suggesting that biliary excretion of ciprofloxacin is a minor
contribution to the rapid fall in serum concentration when compared with diffusion
into the tissues.
An alternative explanation is that ciprofloxacin excreted in the bile is mainly
reabsorbed by the enterohepatic circulation, thereby restoring falling serum
levels.1324 C.S. BALL et al.
FIGURE 3
21.2
.D
200 300
TIME (rain)
6o sb0 d0
Figure 3 Ciprofloxacin CBD concentrations (mg/1) following a 100mg iv bolus dose, administered at
varying times up to 8 hours before anaesthetic induction, in patients with unobstructed (*) partially
obstructed (o) or completely obstructed (o) CBDs. Comparison with predicted ciprofloxacin CBD levels
for unobstructed ), partially obstructed and completely obstructed CBDs.
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Figure 4 Ciprofloxacin CBD concentrations (mg/l) following a 200mg iv bolus dose, administered at
varying times up to 8 hours before anaesthetic induction, in patients with unobstructed (*), partially
obstructed (o) or completely obstructed (o) CBDs. Comparison with predicted ciprofloxacin CBD levels
for unobstructed .) CBDs.THE PHARMACOKINETICS OF THE BILIARY EXCRETION OF CIPROFLOXACIN 325
At toth the doses studied, ciprofloxacin appeared in high concentration in
common duct bile within 20 minutes of its infusion. The early decay of the
exponential curves probably reflects the rapid diffusion of the drug into the tissues.
However, useful concentrations were maintained for up to 8 hours particularly after
a 200 mg dose. It would appear that one hour before anaesthetic induction would be
the ideal time to give this antibiotic as an intravenous infusion. In both groups
common duct bile concentration decreased as the degree of obstruction increased. A
remarkable feature of this study was the finding of clinically significant
concentrations of the antibiotic in the bile from ducts that had been completely
obstructed for up to two months. Perhaps the antibiotic diffuses directly into the
common bile duct from the rich arterial plexuses of the common duct wall.
This study was designed to assess the pharmocokinetics of biliary extretion of this
antibiotic and not prophylactic potential, but the results have relevance to
prophylaxis. Escherichia coli, Klebsiella and Proteus account for about 90% of the
organisms cultured from bile and ciprofloxacin exhibits good activity against these
12 orgamsms, the MIC90 being less than 0.25 mg/1 These organisms and
Staphylococcus aureus from the skin of the patient and his attendants are responsible
for more than 95% of wound infections following biliary surgery. A variety of other
organisms may be found infrequently in the bile. Of these infrequent pathogens,
Streptococcusfaecalis and clostridia are found more frequently. These two organisms
have an MIC90 for ciprofloxacin of 2 mg/1.
Streptococcus faecalis has been cultured occasionally from an infected wound but
we have never isolated clostridia from a wound infection following biliary surgery.
Ciprofloxacin shows poor activity against Bacteriodes fragilis which has an MIC90 of
8 mg/1 but fortunately this is a rare pathogen in bilea’3. A concentration of 2 mg/l
should therefore protect against all but the rare anaerobic pathogens. In common
duct bile this level was achieved within 20 minutes at both doses, and in the majority
of functioning gall bladders this level was greatly exceeded. With the 100 mg dose
common duct concentrations fell below 2 mg/1 after 3.5 hours, but with 200 mg
remained above this level for 8.5 hours. Concentrations of 0.25 mg/! should protect
against 90% of biliary pathogens, a level exceeded for over 8 hours in partial duct
obstruction and for over 2 hours when complete obstruction was present. Although
simple cholecystectomy should take less than an hour, complex biliary operations
where the bile is inevitably infected may take 6 hours. Tissue concentration,
although not measured in the study, has been shown to reach twice the serum
concentration8. For prophylaxis in biliary tract surgery, serum and tissue
coneentrations may be as important as those in the bile1. The number of patients
studied was too small for the mathematical models reported to be considered as
sufficiently accurate for predicting ciprofloxacin concentrations in individual
patients. A much larger series would be required to achieve that and the statistical
analysis would have to be extended to take into account any important characteristics
(e.g. age, sex, weight) which may influence rate of dispersal.
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INVITED COMMENTARY
The quinolone group of antimicrobial agents will unquestionably play a major part
in the treatment and prophylaxis of patient requiring hepatobiliary surgery. This
paper examines the pharmacokinetics of 100 and 200 mg intravenous infusions of
Ciprofloxacin in patients undergoing biliary surgery. The incidence of clinical sepsis
was low. The concentrations of Ciprofloxacin achieved in serum, common bile duct
and gall bladder bile were high and reasonably well sustained. As in all other
publications in which the pharmacokinetics of antimicrobials in biliary disease have
been examined, levels were inversely related to the degree of obstruction.
The anique feature of this communication relates to a mathematical model which
has been used to predict serum and bile duct concentrations depending on the time
of administration, the dose of antimicrobial and the degree of obstruction.
Unfortunately, this last variable is subjective using the analysis designed for these
predictive parameters. More helpful would have been a model which had related
serum and bile levels to serum bilirubin concentration. Nevertheless, the model
seems to have been successful in non-obstructive patients. It is a pity that the
numbers of patients with bile duct obstruction were too small to allow numerical
analysis of their data. It is, of course, patients with bile duct obstruction that present
the highest risk from infection in biliary surgery and it is precisely these patients in
whom a mathematical model should be tested.THE PHARMACOKINETICS OFTHE BILIARY EXCRETION OF CIPROFLOXACIN 327
The data presented by these authors is by no means unique. Serum and bile
concentrations of Ciprofloxacin have been reported by other groups. More
importantly, tissue concentrations, which seem to be very high with the quinolones,
have also been clearly identified by other authors. It is a pity that these investigators
have not taken the opportunity to assay levels of Ciprofloxacin in liver gall bladder
wall and in the pancreas amongst patients requiring pancreatic resection. Despite
these criticisms, the contribution is an important one and marks real progress in new
agents which have considerable therapeutic potential for hepatobiliary infections.
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